First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.

Vidya PereraJoseph M LuettgenZhaoqing WangCharles E FrostCynthia YonesCesare RussoJohn LeeYue ZhaoFrank P LaCretaXuewen MaRobert M KnabbDietmar SeiffertMary DeSouzaPierre MugnierBrenda CirincioneTakayo UenoRobert J A Frost

Published in: British journal of clinical pharmacology (2018)

BMS-962212 has tolerability, PK and PD properties suitable for investigational use as an acute antithrombotic agent in Japanese or non-Japanese subjects.

Keyphrases

small molecule
endothelial cells
liver failure
open label
respiratory failure
drug induced
phase ii
acute respiratory distress syndrome
induced pluripotent stem cells
extracorporeal membrane oxygenation
mechanical ventilation